Akebia Therapeutics Inc. buy Piper Sandler
Start price
14.03.25
/
50%
€1.97
Target price
14.03.26
€5.53
Performance (%)
-28.13%
Price
12.12.25
€1.38
Summary
This prediction is currently active. The price of Akebia Therapeutics Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -28.13%. This prediction currently runs until 14.03.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 5.327% | 5.327% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at Piper Sandler from $4.00 to $6.00. They now have an "overweight" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
31.05.23
31.05.23
-
31.05.24
31.05.24
13.76%
01.06.24
01.06.24
